Last reviewed · How we verify
Naltrexone block
At a glance
| Generic name | Naltrexone block |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Dizziness/drowsiness
- Nausea, gastrointestinal discomfort, vomiting.
- Shaking
- Asymptomatic non-sustained ventricular tachycardia
- Catheter-related asymptomatic uncomplicated right upper extremity superficial venous thrombophlebiti
- Presyncopal episode, likely vasovagal response
- Right lower lung subcentimeter pleural based nodular density
- Incidental PET CT- Right upper lung subcentimeter nodule associated with hypermetabolism
- Incidental PET CT- Nonspecific subpleural nodules
- Nausea
- Feels foggy
Key clinical trials
- Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) (PHASE1)
- Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses (PHASE4)
- Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults (PHASE4)
- Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (PHASE2)
- Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101) (PHASE1)
- Evaluation of Oral PF614 Relative to OxyContin (PF614-102) (PHASE1)
- An Investigation of the Effects of Opioid Receptor Blockade on Changes in Self-esteem and Social Attention (NA)
- Study of Naltrexone-Induced Blockade of Antidepressant Effects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naltrexone block CI brief — competitive landscape report
- Naltrexone block updates RSS · CI watch RSS
- Pfizer portfolio CI